# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-123680
Filing Date
2025-05-21
Accepted
2025-05-21 08:45:49
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | d921291ddefa14a.htm | DEFA14A | 12781
2 | GRAPHIC | g921291page006.jpg | GRAPHIC | 328888
3 | GRAPHIC | g921291page007.jpg | GRAPHIC | 447270
| Complete submission text file | 0001193125-25-123680.txt |  | 1083347

Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33038 | Film No.: 25970994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)